SUBSEQUENT MELANOMA AND NON-MELANOMA SKIN CANCER

Consensus-based recommendation for surveillance of subsequent melanoma and non-melanoma skin cancer

This page is part of the PanCare follow-up recommendations for surveillance of late effects. Click here, for more information on these recommendations.

Who is at risk for melanoma and non-melanoma skin cancer?

CAYA cancer survivors treated with

  • any radiotherapy, including TBI, predominantly in the radiotherapy field
  • HSCT, especially with a history of skin GvHD

What problems might occur?

  • Basal cell carcinoma

  • Squamous cell carcinoma
  • Melanoma

What surveillance modality should be used and at what frequency should it be performed?

  • Self-examination for new spots and changing moles, at least every 6 months
  • History at least every 2 years, starting at entry into long-term follow-up
  • Skin exam at least every 2 years, starting at entry into long-term follow-up

What should be done if abnormalities are identified?

  • Refer to a dermatologist

a The working group considered guidelines for the following subsequent malignant neoplasms that can occur in CAYA cancer survivors: acute myeloid leukaemia, bladder cancer, breast cancer, bone cancer, cervical cancer, CNS neoplasms, endometrial cancer, gastro-intestinal cancer, lung cancer, melanoma and non-melanoma skin cancer, oral cancer, prostate cancer, thyroid cancer, and testicular cancer. No recommendations could be formulated for cervical, endometrial, prostate and testicular cancer. We acknowledge that there might also be an increased risk of other subsequent neoplasms, but no recommendations can be made for surveillance at this time.

b Surveillance tests are specified in the IGHG guidelines for subsequent breast cancer, thyroid cancer and CNS neoplasm surveillance, and in the consensus-based recommendations for colorectal cancer and melanoma and non-melanoma skin cancer surveillance.

c Further recommendations regarding lower urinary tract problems are specified in the Consensus-based recommendation for lower urinary tract problems.

d Further recommendations regarding surveillance of bone problems are specified in the Consensus-based recommendation for bone problems.

e Further recommendations regarding dental and oral exams are specified in the Consensus-based recommendation for dental and oral problems and the Consensus-based recommendation for health promotion.

f Further recommendations regarding dental and oral exams are specified in the Consensus-based recommendation for dental and oral problems and the Consensus-based recommendation for health promotion.